Get the Stockscreener App
4.59
2.46%
0.11
Abeona Therapeutics Inc stock is traded at $4.59, with a volume of 1.31M.
It is up +2.46% in the last 24 hours and down -16.24% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$4.48
Open:
$4.46
24h Volume:
1.31M
Relative Volume:
0.86
Market Cap:
$248.74M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-1.7791
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
+1.77%
1M Performance:
-16.24%
6M Performance:
-28.50%
1Y Performance:
-23.24%
1-Day Range:
$4.42
$4.63
1-Week Range:
$4.16
$4.63
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.59 | 242.78M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Liquidity Mapping Around (ABEO) Price Events - news.stocktradersdaily.com
What technical patterns form on Abeona Therapeutics Inc. (PCJ) stock chartsJuly 2025 Recap & High Accuracy Investment Entry Signals - newser.com
How Abeona Therapeutics Inc. (PCJ) stock behaves in tightening cyclesGold Moves & Verified Momentum Stock Alerts - newser.com
What downside risks could hit Abeona Therapeutics Inc. (PCJ) stockExit Point & Reliable Price Breakout Alerts - newser.com
Abeona Therapeutics Earnings Call: Positive Outlook Amid Challenges - MSN
Is Abeona Therapeutics Inc. (PCJ) stock positioned for digital growth eraIPO Watch & Low Risk Investment Opportunities - newser.com
Is Abeona Therapeutics Inc. (PCJ) stock trading at attractive multiples2025 Price Momentum & Weekly High Potential Alerts - newser.com
Visualizing Abeona Therapeutics Inc. stock with heatmapsVolume Spike & Community Trade Idea Sharing - newser.com
Will Abeona Therapeutics Inc. stock benefit from green energy trendsTrade Risk Summary & Risk Controlled Stock Pick Alerts - newser.com
Sentiment analysis tools applied to Abeona Therapeutics Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Is Abeona Therapeutics Inc a good long term investmentDividend Reinvestment Plans & Market-Leading Growth Rates - earlytimes.in
Is Abeona Therapeutics Inc. (PCJ) stock supported by free cash flowJuly 2025 Summary & Real-Time Volume Analysis Alerts - newser.com
Sector ETF performance correlation with Abeona Therapeutics Inc.2025 Historical Comparison & Weekly Watchlist for Hot Stocks - newser.com
How Abeona Therapeutics Inc. stock reacts to inflationary pressuresMarket Trend Report & Weekly High Conviction Trade Ideas - newser.com
Can Abeona Therapeutics Inc. (PCJ) stock survive global slowdownQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Abeona Therapeutics: Q3 2025 Financial Insights - MSN
Director’s Bold Move: Abeona Therapeutics Stock Sale Shakes Market! - TipRanks
Insider Sell Alert: Mark Alvino Sells 15,000 Shares of Abeona Th - GuruFocus
Dir Alvino Sells 15,000 ($71.2K) Of Abeona Therapeutics Inc [ABEO] - TradingView
ABEONA THERAPEUTICS Director Mark Alvino Sells 15,000 Shares - TradingView
Abeona Therapeutics at Stifel 2025 Healthcare Conference: Strategic Progress and Challenges - Investing.com Canada
Abeona anticipates 2026 profitability as ZEVASKYN demand doubles and QTC network expands - MSN
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates - MarketScreener
Abeona Therapeutics (ABEO) Is Up 17.9% After Reporting Narrowed Losses and ZEVASKYN J-code Approval - Yahoo Finance
Abeona Therapeutics: Q3 Earnings Snapshot - New Haven Register
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):